Palatin Technologies (NYSEAMERICAN:PTN) Posts Earnings Results, Beats Expectations By $0.87 EPS

Palatin Technologies (NYSEAMERICAN:PTN) issued its quarterly earnings data on Wednesday. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.87, FiscalAI reports. The business had revenue of $3.92 million for the quarter, compared to analyst estimates of $1.28 million.

Here are the key takeaways from Palatin Technologies’ conference call:

• Palatin said its once-weekly MC4R-selective peptide obesity program remains on track for an IND submission in Q4 2026, and management said the candidate has entered IND-enabling studies.
• The company highlighted progress on its next-generation oral MC4R agonist, saying preclinical data show improved selectivity, higher potency, and minimal MC1R activity, with an IND targeted for 1H 2027.
• Management said it is prioritizing compounds that could be best-in-class, which contributed to the decision to move away from PL7737 in favor of newer backup candidates with better selectivity and drug-like characteristics.
• Palatin reported $3.9 million in collaboration and license revenue for the quarter, driven by the Altanispac agreement, and said cash plus expected receivables should fund operations through June 30, 2027.
• Beyond the obesity pipeline, Palatin pointed to non-dilutive partnership income from Boehringer Ingelheim and Altanispac, and said its PL8177 ulcerative colitis program remains available for potential partnering after positive phase II proof-of-concept data.

Palatin Technologies Price Performance

Shares of NYSEAMERICAN PTN traded down $0.11 during mid-day trading on Friday, reaching $14.82. 20,382 shares of the company’s stock were exchanged, compared to its average volume of 22,487. The firm’s fifty day moving average is $20.34. Palatin Technologies has a twelve month low of $4.51 and a twelve month high of $31.00.

Institutional Trading of Palatin Technologies

Large investors have recently bought and sold shares of the business. Superstring Capital Management LP acquired a new stake in Palatin Technologies during the 4th quarter worth approximately $522,000. Perceptive Advisors LLC bought a new stake in shares of Palatin Technologies during the fourth quarter worth $1,077,000. Millennium Management LLC bought a new stake in shares of Palatin Technologies during the fourth quarter worth $206,000. Janus Henderson Group PLC acquired a new stake in shares of Palatin Technologies during the fourth quarter worth $2,195,000. Finally, Logos Global Management LP bought a new stake in Palatin Technologies in the 4th quarter valued at $2,153,000. 11.50% of the stock is owned by institutional investors.

About Palatin Technologies

Palatin Technologies, Inc (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.

Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization.